Anthropic's Claude AI discovers new enzyme system in landmark biolab experiment

Anthropic announced that its Claude AI has identified what the company describes as a novel enzyme system lurking within a vast genetic database—a breakthrough the firm is positioning as evidence of artificial intelligence's growing capacity for scientific discovery.

The discovery#

Running roughly 950 Claude agents in parallel for 21 hours and consuming 210 million tokens, the system scanned through DNA sequence data until one instance detected an anomalous repeating pattern. Human researchers then validated this signal through further analysis and experimental work in the lab, ultimately confirming the presence of what Anthropic characterizes as a previously unknown enzyme system housed within bacteriophages—viruses that target bacteria.

Anthropic acknowledged that the company's scientists' role was minimal beyond formulating the initial search prompt and conducting the subsequent laboratory validation.

Uncertain prospects#

While Anthropic draws a comparison to the transformative gene-editing technology Crispr, the practical value and eventual applications of this enzyme system remain unclear. The company has been candid that it is still investigating what biological function the system performs. The relatively early-stage announcement reflects Anthropic's dual aim: demonstrating Claude's scientific prowess and inviting the broader research community to engage with the company's efforts.

A broader AI race in science#

The initiative aligns with a widening trend among leading AI firms to leverage their models for scientific problem-solving. OpenAI has similarly pursued advanced mathematical challenges, often setting aside conventional academic customs in the process. For Anthropic, the biolab effort is also a recruitment tool—the company is seeking to attract scientific talent while expanding into adjacent domains like drug discovery as it prepares for a potential public listing.